select trial semaglutide cardiovascular outcomes without diabetes 2023 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Frontiers | Effects of subcutaneous

Several FDA approved IV iron formulations are available, and each has its own infusion time, dosing schedule, and clinical profile

The more interesting part is what is going on underneath

Oftentimes, we experience mid-afternoon slumps or low energy, which is actually, unknowingly related to gut health, according to Hutchinson

5 As a clinician I am beginning to see clients with eating disorders (ED) explore the use of skinny jabs

Clinical studies have shown that the major effects of GLP-1RA in humans are regulation of blood levels or gut motility

KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease